Systemic sclerosis, also known as scleroderma, is a rare and complex autoimmune
connective-tissue disease. Once considered an untreatable and unpredictable condition …

A proportion of patients with certain types of interstitial lung disease (ILD), including chronic
hypersensitivity pneumonitis and ILDs associated with autoimmune diseases, develop a …

Objective: Some patients with interstitial lung diseases (ILDs) other than idiopathic
pulmonary fibrosis (IPF) develop a progressive fibrosing phenotype. We investigated the …

Objectives SSc is characterized by fibrotic changes in the skin and lung, and the mainstay of
treatment has been CYC. B cell involvement suggests that rituximab (RTX) may also be of …

Background Proposed criteria for progressive fibrosing interstitial lung disease (PF-ILD)
have been linked to increased mortality risk, but lung function trajectory after satisfying …

Systemic sclerosis (SSc) is a rare, systemic autoimmune disease of unknown etiology.
Among the systemic rheumatic diseases, SSc carries the highest mortality, in part due to the …

Pulmonary complications in CTD are common and can involve the interstitium, airways,
pleura and pulmonary vasculature. ILD can occur in all CTD (CTD‐ILD), and may vary from …

Intestinal fibrosis is considered an inevitable complication of Crohn's disease (CD) that
results in symptoms of obstruction and stricture formation. Endoscopic or surgical treatment …

Background Rituximab is often used as rescue therapy in interstitial lung disease (ILD)
associated with connective tissue disease (CTD), but has not been studied in clinical trials …

Idiopathic inflammatory myopathies, including polymyositis (PM), dermatomyositis (DM), and
clinically amyopathic DM (CADM), are a diverse group of autoimmune diseases …